Applied Proteomics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Series C | Alive

Total Raised


Last Raised

$28M | 9 yrs ago

About Applied Proteomics

Applied Proteomics develops a protein biomarker discovery platform. API's systems control and computational expertise as well as recent technologies (improved instrumentation, faster computing, and genome annotations) make proteomics-based biomarker discovery possible as a replicable, industrial application. API has demonstrated that its approach leads to superior data (better signal, less noise), which leads to better results (more protein features and biomarkers observed). Better results will lead to improved diagnostics and a more efficient and effective healthcare system.

Applied Proteomics Headquarter Location

3545 John Hopkins Court Suite 150

San Diego, California, 92121,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Applied Proteomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Applied Proteomics is included in 2 Expert Collections, including Omics.



1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Biopharma Tech

838 items

Applied Proteomics Patents

Applied Proteomics has filed 10 patents.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Bioinformatics
  • Conditions of the mucous membranes
patents chart

Application Date

Grant Date


Related Topics




Autoimmune diseases, Rare diseases, Inflammations, Psychiatric diagnosis, Autosomal recessive disorders


Application Date


Grant Date



Related Topics

Autoimmune diseases, Rare diseases, Inflammations, Psychiatric diagnosis, Autosomal recessive disorders



Latest Applied Proteomics News

Mason researchers to provide biostatistics and bioinformatic analysis for new project

Sep 6, 2020

Reviewed by Emily Henderson, B.Sc.Sep 5 2020 Virginia Espina, Research Associate Professor, Applied Proteomics and Molecular Medicine, received $21,000 from Baylor Research Institute for a project in which Mason researchers are providing biostatistics and bioinformatic analysis for integrating multi-omic data sets from a breast cancer cohort. Specimens are from patients with triple-negative breast tumors. Data analysis will include correlations between proteomic, metabolomic, genomic, and/or clinical data. Mason researchers will analyze additional reverse phase protein array (RPPA) endpoints based on the findings of the multi-omic correlative analyses. RPPA is a technology that allows for quantification of one protein or phosphoprotein in multiple samples under the same experimental conditions at the same time. Funding for this project began in late July 2020 and will end in late July 2021. Source:

  • Where is Applied Proteomics's headquarters?

    Applied Proteomics's headquarters is located at 3545 John Hopkins Court, San Diego.

  • What is Applied Proteomics's latest funding round?

    Applied Proteomics's latest funding round is Series C.

  • How much did Applied Proteomics raise?

    Applied Proteomics raised a total of $50.5M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.